Academic Study Confounds Latest UK Zytiga Reimbursement Consultation
Executive Summary
Janssen, the Institute of Cancer Research and patient groups have reacted with disappointment to NICE draft guidance recommending that Zytiga should not be funded by England's National Health Service in a subset of prostate cancer patients. But the existence of an academic study has complicated the situation in an unusual way, and Janssen still hopes to steer a path to reimbursement.